Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.

West Virginia University microbiologists have identified an antibody that can kill one of the most drug-resistant bacteria.

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Researchers identified that the dominant B cell epitope of Lachnospiraceae flagellins and the utilization of the flagellin ...

Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...